Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2

Overview

Journal Trends Pharmacol Sci

Specialty Pharmacology

Date 2020 Aug 25

PMID 32829936

Citations 63

Authors

Alex Renn

Ying Fu

Xin Hu

Matthew D Hall

Anton Simeonov

Affiliations

Soon will be listed here.

Abstract

With the recent spread of severe acute respiratory syndrome coronavirus (SARS-CoV-2)_ infecting >16 million people worldwide as of 28 July 2020, causing >650 000 deaths, there is a desperate need for therapeutic agents and vaccines. Building on knowledge of previous outbreaks of SARS-CoV-1 and Middle East respiratory syndrome (MERS), the development of therapeutic antibodies and vaccines against coronavirus disease 2019 (COVID-19) is taking place at an unprecedented speed. Current efforts towards the development of neutralizing antibodies against COVID-19 are summarized. We also highlight the importance of a fruitful antibody development pipeline to combat the potential escape plans of SARS-CoV-2, including somatic mutations and antibody-dependent enhancement (ADE).

Citing Articles

Antibody-dependent enhancement of coronaviruses.

Tao T, Tian L, Ke J, Zhang C, Li M, Xu X Int J Biol Sci. 2025; 21(4):1686-1704.

PMID: 39990674 PMC: 11844293. DOI: 10.7150/ijbs.96112.

Adverse events associated with SARS-CoV-2 neutralizing monoclonal antibodies using the FDA adverse event reporting system database.

Choi M, Oh S, Song Y, Ki S Toxicol Res. 2024; 40(4):673-682.

PMID: 39345748 PMC: 11436521. DOI: 10.1007/s43188-024-00256-x.

Neutralization of SARS-CoV-2 and Intranasal Protection of Mice with a nanoCLAMP Antibody Mimetic.

Pagneux Q, Garnier N, Fabregue M, Sharkaoui S, Mazzoli S, Engelmann I ACS Pharmacol Transl Sci. 2024; 7(3):757-770.

PMID: 38481677 PMC: 10928885. DOI: 10.1021/acsptsci.3c00306.

Self-medication practices against COVID-19 infection and awareness among residents of Mogadishu, Somalia: A cross-sectional analysis.

Moussa A, Omar F, Fiidow O, Ali F, Babatunde S PLoS One. 2023; 18(6):e0284854.

PMID: 37379300 PMC: 10306195. DOI: 10.1371/journal.pone.0284854.

Metallo-antiviral aspirants: .

Mehrotra R, Shukla S, Gaur P Eur J Med Chem Rep. 2023; 8:100104.

PMID: 37035854 PMC: 10070197. DOI: 10.1016/j.ejmcr.2023.100104.

References

Wang C, Li W, Drabek D, Okba N, van Haperen R, Osterhaus A . A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020; 11(1):2251. PMC: 7198537. DOI: 10.1038/s41467-020-16256-y. View

Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X . Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020; 584(7819):115-119. DOI: 10.1038/s41586-020-2380-z. View

Wang Q, Zhang L, Kuwahara K, Li L, Liu Z, Li T . Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates. ACS Infect Dis. 2016; 2(5):361-76. PMC: 7075522. DOI: 10.1021/acsinfecdis.6b00006. View

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y . Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020; 71(16):2027-2034. PMC: 7184337. DOI: 10.1093/cid/ciaa344. View

Hansen J, Baum A, Pascal K, Russo V, Giordano S, Wloga E . Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020; 369(6506):1010-1014. PMC: 7299284. DOI: 10.1126/science.abd0827. View

Tian X, Li C, Huang A, Xia S, Lu S, Shi Z . Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020; 9(1):382-385. PMC: 7048180. DOI: 10.1080/22221751.2020.1729069. View

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620-2629. PMC: 7190990. DOI: 10.1172/JCI137244. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

10.

van Dorp L, Acman M, Richard D, Shaw L, Ford C, Ormond L . Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. Infect Genet Evol. 2020; 83:104351. PMC: 7199730. DOI: 10.1016/j.meegid.2020.104351. View

11.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

12.

Preston B, Poiesz B, Loeb L . Fidelity of HIV-1 reverse transcriptase. Science. 1988; 242(4882):1168-71. DOI: 10.1126/science.2460924. View

13.

Shi R, Shan C, Duan X, Chen Z, Liu P, Song J . A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020; 584(7819):120-124. DOI: 10.1038/s41586-020-2381-y. View

14.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

15.

Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-OCallaghan A, Pardos-Gea J, Quintana A . Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. Autoimmun Rev. 2020; 19(7):102569. PMC: 7252146. DOI: 10.1016/j.autrev.2020.102569. View

16.

Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L . Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. Cell. 2020; 182(1):73-84.e16. PMC: 7231725. DOI: 10.1016/j.cell.2020.05.025. View

17.

Halstead S . Dengue. Lancet. 2007; 370(9599):1644-52. DOI: 10.1016/S0140-6736(07)61687-0. View

18.

Pinto D, Park Y, Beltramello M, Walls A, Tortorici M, Bianchi S . Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020; 583(7815):290-295. DOI: 10.1038/s41586-020-2349-y. View

19.

Rockx B, Donaldson E, Frieman M, Sheahan T, Corti D, Lanzavecchia A . Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. J Infect Dis. 2010; 201(6):946-55. PMC: 2826557. DOI: 10.1086/651022. View

20.

Jackson L, Anderson E, Rouphael N, Roberts P, Makhene M, Coler R . An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020; 383(20):1920-1931. PMC: 7377258. DOI: 10.1056/NEJMoa2022483. View